“Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years”, J of Skin, vol. 7, no. 2, p. s112, Mar. 2023, doi: 10.25251/skin.7.supp.112.